New York Blood Center, Inc.

University of Minnesota

Lanying Du

Shibo Jiang

Yusen Zhou

Fang Li

Marc Kevin Jenkins

Guangyu Zhao

Wanbo Tai

Frank Jonathan Lee

Qibin Geng

Jian Shang

Sung-Wook Hong

Yushun Wan

The present disclosure provides virus like nanoparticles (VLPs), which are capable of displaying multiple copies of a SARS-CoV-2 antigen, for eliciting protective immunity against a SARS-CoV-2 infection, as well as polypeptides, compositions and methods thereof.

Virus like nanoparticle compositions and methods thereof

Provided herein are methods of use of subunit immunogenic compositions, in particular for the prevention and treatment of Zika virus infections.

Zika virus immunogenic compositions

Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

Immunogenic composition for MERS coronavirus infection

Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator.

Immunopotentiator-linked oligomeric influenza immunogenic compositions

Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.

Growing community of inventors

Rego Park, NY, United States of America

Lanying Du